ADIUVO-2 adjuvant therapy trial in high-risk adrenocortical carcinoma

Phase 3, randomised, open-label trial of mitotane, cisplatin and etoposide in adrenal cancer (ACC) (3 arms), sponsored by Uppsala University Hospital, Rigshospitalet, Amsterdam UMC Stichting, Assistance Publique Hopitaux De Paris, Sao Joao University Hospital Center, Universitaetsklinikum Wuerzburg AöR, Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy, University Hospital Centre Zagreb, National Institute Of Endocrinology C.I. Parhon, Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia, Vall D Hebron Institute Of Oncology. Primary endpoint: Recurrence-free survival. Planned start Jul 2024; status: authorised.